Debiopharm appeals to the Supreme Court regarding Elplat

23 February 2017

Family-owned Swiss drugmaker Debiopharm International has filed an appeal before the Supreme Court of Japan against the decision from the IP High Court (a special branch of the Tokyo High Court), according to which the generic products of Elplat (Oxaliplatin) commercialized by Nippon Kayaku have not infringed the Japanese patent JP 4430229 , which is owned by Debiopharm and exclusively licensed to Yakult Honsha in Japan.

Debiopharm continues to take any and all reasonable legal actions against any activity that infringes the intellectual property rights owned by Debiopharm and exclusively licensed to Yakult.

Elplat is an anticancer platinum drug, for which Yakult acquired development and commercialization rights in Japan from Debiopharm in 1997. Elplat was approved for the indication for the treatment of "curatively unresectable advanced/recurrent colorectal cancer" in March 2005, and launched on the market in April of the same year. The drug has since gained approval of added cancer indications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK